Dyckerhoff Stefan A 4

4 · Astera Labs, Inc. · Filed May 11, 2026

AI-generated summary of this filing

Updated May 11, 2026

Astera Labs (ALAB) Director Stefan A. Dyckerhoff Sells Shares

What Happened

Stefan A. Dyckerhoff, a director of Astera Labs, sold 12,499 shares in six open‑market transactions on May 7, 2026. Transactions: 1,783 shares @ $199.00 ($354,817); 4,238 @ $199.00 ($843,362); 336 @ $199.00 ($66,864); 1,722 @ $201.10 ($346,298); 4,095 @ $201.10 (weighted avg; see note) ($823,513); 325 @ $201.10 ($65,358). Total proceeds ≈ $2,500,212. These sales were made pursuant to a Rule 10b5‑1 trading plan adopted December 1, 2025. This filing reports sales (not purchases).

Key Details

Transaction date: May 7, 2026; Form 4 filed: May 11, 2026 (timely — second business day after the trades).
Prices reported: $199.00 and $201.10 (F4: $201.10 is a weighted average for sales at $201.00–$201.40; detailed per‑price breakdown available on request).
Total shares sold: 12,499; Approximate proceeds: $2.5 million.
Shares owned after the transaction: not stated in the provided excerpt.
Notable footnotes:
- F1: Sales executed under a Rule 10b5‑1 trading plan (adopted 12/1/2025).
- F2, F3, F5: Certain shares are held by trusts/partnerships for which the reporting person disclaims beneficial ownership except for pecuniary interest.
- F4: Weighted‑average price disclosure for certain lots; reporting person can provide per‑price sales on request.

Context

Sales executed under a 10b5‑1 plan are pre‑arranged and commonly used for routine liquidity or diversification; they do not necessarily indicate a change in the insider’s view of the company.
This filing reports only sales — no option exercises, awards, or gifts were disclosed in the provided information.

Form 4

Period: 2026-05-07

Director

Transactions

Sale
Common Stock
[F1]
2026-05-07$199.00/sh−1,783$354,817→ 65,361 total
Sale
Common Stock
[F1][F2]
2026-05-07$199.00/sh−4,238$843,362→ 332,160 total(indirect: By Trust)
Sale
Common Stock
[F1][F3]
2026-05-07$199.00/sh−336$66,864→ 6,278 total(indirect: By Partnership)
Sale
Common Stock
[F1][F4]
2026-05-07$201.10/sh−1,722$346,298→ 63,639 total
Sale
Common Stock
[F1][F4][F2]
2026-05-07$201.10/sh−4,095$823,513→ 328,065 total(indirect: By Trust)
Sale
Common Stock
[F1][F4][F3]
2026-05-07$201.10/sh−325$65,358→ 5,953 total(indirect: By Partnership)

Holdings

Footnotes (5)

[F1]Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025.
[F2]Shares held by a trust of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
[F3]Shares held by a limited partnership of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.00 to $201.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]Shares held by an irrevocable trust of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Signature

/s/ Kanwalpreet S. Kalra, Attorney-in-Fact|2026-05-11

1 file